Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -121.76% is 116% below its 5-year average of -56.46%, near the low end of its 5-year range (-121.76%–-37.86%).
As of the fiscal period ended Tuesday, June 30, 2026. 63.89% below its 12-month average of -74.29%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -121.76%.
RETURN ON EQUITY (ROE)
-121.76%
RETURN ON EQUITY (ROE) AVG TTM
-74.29%
RETURN ON EQUITY (ROE) AVG 3Y
-58.73%
RETURN ON EQUITY (ROE) AVG 5Y
-56.46%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-63.89%
CURRENT VS 3Y AVG
-107.33%
CURRENT VS 5Y AVG
-115.65%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 753 covered companies
CURRENT VS SECTOR MEDIAN
-189.83%
vs the sector median at left
Zentalis Pharmaceuticals, Inc.
Market Cap
$190.07M
Return on Equity (ROE)
-121.76%
TTM Avg
-74.29%
3Y Avg
-58.73%
5Y Avg
-56.46%
Market Cap
$189.11M
Return on Equity (ROE)
-136.83%
TTM Avg
-43.45%
3Y Avg
-452.04%
5Y Avg
-306.86%
Market Cap
$192.49M
Return on Equity (ROE)
-17.83%
TTM Avg
-11.95%
3Y Avg
-32.11%
5Y Avg
-28.82%
Market Cap
$197.18M
Return on Equity (ROE)
N/A
TTM Avg
213.11%
3Y Avg
66.34%
5Y Avg
24.75%
Market Cap
$182.60M
Return on Equity (ROE)
-47.78%
TTM Avg
-64.50%
3Y Avg
-55.96%
5Y Avg
-125.52%
Market Cap
$197.87M
Return on Equity (ROE)
-154.90%
TTM Avg
-136.39%
3Y Avg
-122.19%
5Y Avg
-93.38%
Market Cap
$198.33M
Return on Equity (ROE)
N/A
TTM Avg
620.74%
3Y Avg
332.27%
5Y Avg
266.26%
Market Cap
$180.47M
Return on Equity (ROE)
-21.57%
TTM Avg
-470.91%
3Y Avg
-299.18%
5Y Avg
-180.76%
Market Cap
$179.75M
Return on Equity (ROE)
-44.23%
TTM Avg
-36.61%
3Y Avg
-30.86%
5Y Avg
-42.66%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Zentalis Pharmaceuticals, Inc. (ZNTL) | $190.07M | -121.76% | -74.29% | -58.73% | -56.46% |
| Eledon Pharmaceuticals, Inc. (ELDN)vs › | $189.11M | -136.83% | -43.45% | -452.04% | -306.86% |
| RxSight, Inc. (RXST)vs › | $192.49M | -17.83% | -11.95% | -32.11% | -28.82% |
| Surrozen, Inc. (SRZN)vs › | $197.18M | N/A | 213.11% | 66.34% | 24.75% |
| AN2 Therapeutics, Inc. (ANTX)vs › | $182.60M | -47.78% | -64.50% | -55.96% | -125.52% |
| Exagen Inc. (XGN)vs › | $197.87M | -154.90% | -136.39% | -122.19% | -93.38% |
| Cartesian Therapeutics, Inc. (RNAC)vs › | $198.33M | N/A | 620.74% | 332.27% | 266.26% |
| Canton Strategic Holdings Inc (CNTN)vs › | $180.47M | -21.57% | -470.91% | -299.18% | -180.76% |
| Compass Therapeutics, Inc. (CMPX)vs › | $179.75M | -44.23% | -36.61% | -30.86% | -42.66% |
| Oramed Pharmaceuticals Inc. (ORMP)vs › | $179.26M | 55.08% | 9.52% | -0.62% | -4.34% |
ROE
-121.8%
ROA
-81.2%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -121.76% |
| 2026-03-31 | -67.95% |
| 2025-12-31 | -63.39% |
| 2025-09-30 | -59.05% |
| 2025-06-30 | -59.30% |
| 2025-03-31 | -75.90% |
| 2024-12-31 | -49.18% |
| 2024-09-30 | -50.60% |
| 2024-06-30 | -50.88% |
| 2024-03-31 | -47.72% |
| 2023-12-31 | -66.82% |
| 2023-09-30 | -59.42% |
| 2023-06-30 | -54.50% |
| 2023-03-31 | -62.50% |
| 2022-12-31 | -54.59% |
| 2022-09-30 | -54.12% |
| 2022-06-30 | -38.45% |
| 2022-03-31 | -53.25% |
| 2021-12-31 | -43.61% |
| 2021-09-30 | -37.86% |
| 2021-06-30 | -80.11% |
| 2021-03-31 | -56.49% |
| 2020-12-31 | -38.19% |
| 2020-09-30 | -26.99% |
| 2020-06-30 | -32.75% |
| 2019-12-31 | -74.13% |
